

COVID-19 Impact on Global Selective Agonists Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/CD7C33B84445EN.html>

Date: July 2020

Pages: 153

Price: US\$ 3,900.00 (Single User License)

ID: CD7C33B84445EN

Abstracts

This report focuses on the global Selective Agonists status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Merck

Bausch Health Companies

Pfizer

Sterling Winthrop

Sanofi

Paragon BioTeck

West-Ward Pharmaceuticals

Biosyent Pharma

Novartis

Omega Laboratories

Medical Purchasing Solutions

Avadel Legacy Pharmaceuticals

Amneal Biosciences

Cipla USA

Par Pharmaceutical

Glaxosmithkline

Teva

Bayer

Impax Generics

Mylan Pharmaceuticals

Physicians Total Care

Cadila Pharmaceuticals

Alembic Pharmaceuticals

Allergan

Mylan

Market segment by Type, the product can be split into

?1 Selective Agonists

?2 Selective Agonists

?1 Selective Agonists

?2 Selective Agonists

Market segment by Application, split into

Paroxysmal Supraventricular Tachycardia

Eye Drops

Anaphylaxis

Cardiac Arrest

Anaphylaxis

Cardiac Arrest

Chronic Heart Failure

Myocardial Infarction

Postoperative Hypotension

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Selective Agonists status, future forecast, growth opportunity, key market and key players.

To present the Selective Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Selective Agonists are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Selective Agonists Revenue
- 1.4 Market Analysis by Type
 - 1.4.1 Global Selective Agonists Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 ?1 Selective Agonists
 - 1.4.3 ?2 Selective Agonists
 - 1.4.4 ?1 Selective Agonists
 - 1.4.5 ?2 Selective Agonists
- 1.5 Market by Application
 - 1.5.1 Global Selective Agonists Market Share by Application: 2020 VS 2026
 - 1.5.2 Paroxysmal Supraventricular Tachycardia
 - 1.5.3 Eye Drops
 - 1.5.4 Anaphylaxis
 - 1.5.5 Cardiac Arrest
 - 1.5.6 Anaphylaxis
 - 1.5.7 Cardiac Arrest
 - 1.5.8 Chronic Heart Failure
 - 1.5.9 Myocardial Infarction
 - 1.5.10 Postoperative Hypotension
- 1.6 Coronavirus Disease 2019 (Covid-19): Selective Agonists Industry Impact
 - 1.6.1 How the Covid-19 is Affecting the Selective Agonists Industry
 - 1.6.1.1 Selective Agonists Business Impact Assessment - Covid-19
 - 1.6.1.2 Supply Chain Challenges
 - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
 - 1.6.2 Market Trends and Selective Agonists Potential Opportunities in the COVID-19 Landscape
 - 1.6.3 Measures / Proposal against Covid-19
 - 1.6.3.1 Government Measures to Combat Covid-19 Impact
 - 1.6.3.2 Proposal for Selective Agonists Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Selective Agonists Market Perspective (2015-2026)
- 2.2 Selective Agonists Growth Trends by Regions
 - 2.2.1 Selective Agonists Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 Selective Agonists Historic Market Share by Regions (2015-2020)
 - 2.2.3 Selective Agonists Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Challenges
 - 2.3.4 Porter's Five Forces Analysis
 - 2.3.5 Selective Agonists Market Growth Strategy
 - 2.3.6 Primary Interviews with Key Selective Agonists Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Selective Agonists Players by Market Size
 - 3.1.1 Global Top Selective Agonists Players by Revenue (2015-2020)
 - 3.1.2 Global Selective Agonists Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Selective Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Selective Agonists Market Concentration Ratio
 - 3.2.1 Global Selective Agonists Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by Selective Agonists Revenue in 2019
- 3.3 Selective Agonists Key Players Head office and Area Served
- 3.4 Key Players Selective Agonists Product Solution and Service
- 3.5 Date of Enter into Selective Agonists Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

- 4.1 Global Selective Agonists Historic Market Size by Type (2015-2020)
- 4.2 Global Selective Agonists Forecasted Market Size by Type (2021-2026)

5 SELECTIVE AGONISTS BREAKDOWN DATA BY APPLICATION (2015-2026)

- 5.1 Global Selective Agonists Market Size by Application (2015-2020)
- 5.2 Global Selective Agonists Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

- 6.1 North America Selective Agonists Market Size (2015-2020)
- 6.2 Selective Agonists Key Players in North America (2019-2020)
- 6.3 North America Selective Agonists Market Size by Type (2015-2020)
- 6.4 North America Selective Agonists Market Size by Application (2015-2020)

7 EUROPE

- 7.1 Europe Selective Agonists Market Size (2015-2020)
- 7.2 Selective Agonists Key Players in Europe (2019-2020)
- 7.3 Europe Selective Agonists Market Size by Type (2015-2020)
- 7.4 Europe Selective Agonists Market Size by Application (2015-2020)

8 CHINA

- 8.1 China Selective Agonists Market Size (2015-2020)
- 8.2 Selective Agonists Key Players in China (2019-2020)
- 8.3 China Selective Agonists Market Size by Type (2015-2020)
- 8.4 China Selective Agonists Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Selective Agonists Market Size (2015-2020)
- 9.2 Selective Agonists Key Players in Japan (2019-2020)
- 9.3 Japan Selective Agonists Market Size by Type (2015-2020)
- 9.4 Japan Selective Agonists Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Selective Agonists Market Size (2015-2020)
- 10.2 Selective Agonists Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Selective Agonists Market Size by Type (2015-2020)
- 10.4 Southeast Asia Selective Agonists Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Selective Agonists Market Size (2015-2020)
- 11.2 Selective Agonists Key Players in India (2019-2020)
- 11.3 India Selective Agonists Market Size by Type (2015-2020)

11.4 India Selective Agonists Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Selective Agonists Market Size (2015-2020)

12.2 Selective Agonists Key Players in Central & South America (2019-2020)

12.3 Central & South America Selective Agonists Market Size by Type (2015-2020)

12.4 Central & South America Selective Agonists Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Merck

13.1.1 Merck Company Details

13.1.2 Merck Business Overview and Its Total Revenue

13.1.3 Merck Selective Agonists Introduction

13.1.4 Merck Revenue in Selective Agonists Business (2015-2020)

13.1.5 Merck Recent Development

13.2 Bausch Health Companies

13.2.1 Bausch Health Companies Company Details

13.2.2 Bausch Health Companies Business Overview and Its Total Revenue

13.2.3 Bausch Health Companies Selective Agonists Introduction

13.2.4 Bausch Health Companies Revenue in Selective Agonists Business (2015-2020)

13.2.5 Bausch Health Companies Recent Development

13.3 Pfizer

13.3.1 Pfizer Company Details

13.3.2 Pfizer Business Overview and Its Total Revenue

13.3.3 Pfizer Selective Agonists Introduction

13.3.4 Pfizer Revenue in Selective Agonists Business (2015-2020)

13.3.5 Pfizer Recent Development

13.4 Sterling Winthrop

13.4.1 Sterling Winthrop Company Details

13.4.2 Sterling Winthrop Business Overview and Its Total Revenue

13.4.3 Sterling Winthrop Selective Agonists Introduction

13.4.4 Sterling Winthrop Revenue in Selective Agonists Business (2015-2020)

13.4.5 Sterling Winthrop Recent Development

13.5 Sanofi

13.5.1 Sanofi Company Details

- 13.5.2 Sanofi Business Overview and Its Total Revenue
- 13.5.3 Sanofi Selective Agonists Introduction
- 13.5.4 Sanofi Revenue in Selective Agonists Business (2015-2020)
- 13.5.5 Sanofi Recent Development
- 13.6 Paragon BioTeck
 - 13.6.1 Paragon BioTeck Company Details
 - 13.6.2 Paragon BioTeck Business Overview and Its Total Revenue
 - 13.6.3 Paragon BioTeck Selective Agonists Introduction
 - 13.6.4 Paragon BioTeck Revenue in Selective Agonists Business (2015-2020)
 - 13.6.5 Paragon BioTeck Recent Development
- 13.7 West-Ward Pharmaceuticals
 - 13.7.1 West-Ward Pharmaceuticals Company Details
 - 13.7.2 West-Ward Pharmaceuticals Business Overview and Its Total Revenue
 - 13.7.3 West-Ward Pharmaceuticals Selective Agonists Introduction
 - 13.7.4 West-Ward Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
 - 13.7.5 West-Ward Pharmaceuticals Recent Development
- 13.8 Biosyent Pharma
 - 13.8.1 Biosyent Pharma Company Details
 - 13.8.2 Biosyent Pharma Business Overview and Its Total Revenue
 - 13.8.3 Biosyent Pharma Selective Agonists Introduction
 - 13.8.4 Biosyent Pharma Revenue in Selective Agonists Business (2015-2020)
 - 13.8.5 Biosyent Pharma Recent Development
- 13.9 Novartis
 - 13.9.1 Novartis Company Details
 - 13.9.2 Novartis Business Overview and Its Total Revenue
 - 13.9.3 Novartis Selective Agonists Introduction
 - 13.9.4 Novartis Revenue in Selective Agonists Business (2015-2020)
 - 13.9.5 Novartis Recent Development
- 13.10 Omega Laboratories
 - 13.10.1 Omega Laboratories Company Details
 - 13.10.2 Omega Laboratories Business Overview and Its Total Revenue
 - 13.10.3 Omega Laboratories Selective Agonists Introduction
 - 13.10.4 Omega Laboratories Revenue in Selective Agonists Business (2015-2020)
 - 13.10.5 Omega Laboratories Recent Development
- 13.11 Medical Purchasing Solutions
 - 10.11.1 Medical Purchasing Solutions Company Details
 - 10.11.2 Medical Purchasing Solutions Business Overview and Its Total Revenue
 - 10.11.3 Medical Purchasing Solutions Selective Agonists Introduction

- 10.11.4 Medical Purchasing Solutions Revenue in Selective Agonists Business (2015-2020)
- 10.11.5 Medical Purchasing Solutions Recent Development
- 13.12 Avadel Legacy Pharmaceuticals
 - 10.12.1 Avadel Legacy Pharmaceuticals Company Details
 - 10.12.2 Avadel Legacy Pharmaceuticals Business Overview and Its Total Revenue
 - 10.12.3 Avadel Legacy Pharmaceuticals Selective Agonists Introduction
 - 10.12.4 Avadel Legacy Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
 - 10.12.5 Avadel Legacy Pharmaceuticals Recent Development
- 13.13 Amneal Biosciences
 - 10.13.1 Amneal Biosciences Company Details
 - 10.13.2 Amneal Biosciences Business Overview and Its Total Revenue
 - 10.13.3 Amneal Biosciences Selective Agonists Introduction
 - 10.13.4 Amneal Biosciences Revenue in Selective Agonists Business (2015-2020)
 - 10.13.5 Amneal Biosciences Recent Development
- 13.14 Cipla USA
 - 10.14.1 Cipla USA Company Details
 - 10.14.2 Cipla USA Business Overview and Its Total Revenue
 - 10.14.3 Cipla USA Selective Agonists Introduction
 - 10.14.4 Cipla USA Revenue in Selective Agonists Business (2015-2020)
 - 10.14.5 Cipla USA Recent Development
- 13.15 Par Pharmaceutical
 - 10.15.1 Par Pharmaceutical Company Details
 - 10.15.2 Par Pharmaceutical Business Overview and Its Total Revenue
 - 10.15.3 Par Pharmaceutical Selective Agonists Introduction
 - 10.15.4 Par Pharmaceutical Revenue in Selective Agonists Business (2015-2020)
 - 10.15.5 Par Pharmaceutical Recent Development
- 13.16 Glaxosmithkline
 - 10.16.1 Glaxosmithkline Company Details
 - 10.16.2 Glaxosmithkline Business Overview and Its Total Revenue
 - 10.16.3 Glaxosmithkline Selective Agonists Introduction
 - 10.16.4 Glaxosmithkline Revenue in Selective Agonists Business (2015-2020)
 - 10.16.5 Glaxosmithkline Recent Development
- 13.17 Teva
 - 10.17.1 Teva Company Details
 - 10.17.2 Teva Business Overview and Its Total Revenue
 - 10.17.3 Teva Selective Agonists Introduction
 - 10.17.4 Teva Revenue in Selective Agonists Business (2015-2020)

- 10.17.5 Teva Recent Development
- 13.18 Bayer
 - 10.18.1 Bayer Company Details
 - 10.18.2 Bayer Business Overview and Its Total Revenue
 - 10.18.3 Bayer Selective Agonists Introduction
 - 10.18.4 Bayer Revenue in Selective Agonists Business (2015-2020)
 - 10.18.5 Bayer Recent Development
- 13.19 Impax Generics
 - 10.19.1 Impax Generics Company Details
 - 10.19.2 Impax Generics Business Overview and Its Total Revenue
 - 10.19.3 Impax Generics Selective Agonists Introduction
 - 10.19.4 Impax Generics Revenue in Selective Agonists Business (2015-2020)
 - 10.19.5 Impax Generics Recent Development
- 13.20 Mylan Pharmaceuticals
 - 10.20.1 Mylan Pharmaceuticals Company Details
 - 10.20.2 Mylan Pharmaceuticals Business Overview and Its Total Revenue
 - 10.20.3 Mylan Pharmaceuticals Selective Agonists Introduction
 - 10.20.4 Mylan Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
 - 10.20.5 Mylan Pharmaceuticals Recent Development
- 13.21 Physicians Total Care
 - 10.21.1 Physicians Total Care Company Details
 - 10.21.2 Physicians Total Care Business Overview and Its Total Revenue
 - 10.21.3 Physicians Total Care Selective Agonists Introduction
 - 10.21.4 Physicians Total Care Revenue in Selective Agonists Business (2015-2020)
 - 10.21.5 Physicians Total Care Recent Development
- 13.22 Cadila Pharmaceuticals
 - 10.22.1 Cadila Pharmaceuticals Company Details
 - 10.22.2 Cadila Pharmaceuticals Business Overview and Its Total Revenue
 - 10.22.3 Cadila Pharmaceuticals Selective Agonists Introduction
 - 10.22.4 Cadila Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
 - 10.22.5 Cadila Pharmaceuticals Recent Development
- 13.23 Alembic Pharmaceuticals
 - 10.23.1 Alembic Pharmaceuticals Company Details
 - 10.23.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
 - 10.23.3 Alembic Pharmaceuticals Selective Agonists Introduction
 - 10.23.4 Alembic Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
 - 10.23.5 Alembic Pharmaceuticals Recent Development

13.24 Allergan

10.24.1 Allergan Company Details

10.24.2 Allergan Business Overview and Its Total Revenue

10.24.3 Allergan Selective Agonists Introduction

10.24.4 Allergan Revenue in Selective Agonists Business (2015-2020)

10.24.5 Allergan Recent Development

13.25 Mylan

10.25.1 Mylan Company Details

10.25.2 Mylan Business Overview and Its Total Revenue

10.25.3 Mylan Selective Agonists Introduction

10.25.4 Mylan Revenue in Selective Agonists Business (2015-2020)

10.25.5 Mylan Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Selective Agonists Key Market Segments
- Table 2. Key Players Covered: Ranking by Selective Agonists Revenue
- Table 3. Ranking of Global Top Selective Agonists Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Selective Agonists Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of ?1 Selective Agonists
- Table 6. Key Players of ?2 Selective Agonists
- Table 7. Key Players of ?1 Selective Agonists
- Table 8. Key Players of ?2 Selective Agonists
- Table 9. COVID-19 Impact Global Market: (Four Selective Agonists Market Size Forecast Scenarios)
- Table 10. Opportunities and Trends for Selective Agonists Players in the COVID-19 Landscape
- Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 12. Key Regions/Countries Measures against Covid-19 Impact
- Table 13. Proposal for Selective Agonists Players to Combat Covid-19 Impact
- Table 14. Global Selective Agonists Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 15. Global Selective Agonists Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 16. Global Selective Agonists Market Size by Regions (2015-2020) (US\$ Million)
- Table 17. Global Selective Agonists Market Share by Regions (2015-2020)
- Table 18. Global Selective Agonists Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 19. Global Selective Agonists Market Share by Regions (2021-2026)
- Table 20. Market Top Trends
- Table 21. Key Drivers: Impact Analysis
- Table 22. Key Challenges
- Table 23. Selective Agonists Market Growth Strategy
- Table 24. Main Points Interviewed from Key Selective Agonists Players
- Table 25. Global Selective Agonists Revenue by Players (2015-2020) (Million US\$)
- Table 26. Global Selective Agonists Market Share by Players (2015-2020)
- Table 27. Global Top Selective Agonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Agonists as of 2019)

Table 28. Global Selective Agonists by Players Market Concentration Ratio (CR5 and HHI)

Table 29. Key Players Headquarters and Area Served

Table 30. Key Players Selective Agonists Product Solution and Service

Table 31. Date of Enter into Selective Agonists Market

Table 32. Mergers & Acquisitions, Expansion Plans

Table 33. Global Selective Agonists Market Size by Type (2015-2020) (Million US\$)

Table 34. Global Selective Agonists Market Size Share by Type (2015-2020)

Table 35. Global Selective Agonists Revenue Market Share by Type (2021-2026)

Table 36. Global Selective Agonists Market Size Share by Application (2015-2020)

Table 37. Global Selective Agonists Market Size by Application (2015-2020) (Million US\$)

Table 38. Global Selective Agonists Market Size Share by Application (2021-2026)

Table 39. North America Key Players Selective Agonists Revenue (2019-2020) (Million US\$)

Table 40. North America Key Players Selective Agonists Market Share (2019-2020)

Table 41. North America Selective Agonists Market Size by Type (2015-2020) (Million US\$)

Table 42. North America Selective Agonists Market Share by Type (2015-2020)

Table 43. North America Selective Agonists Market Size by Application (2015-2020) (Million US\$)

Table 44. North America Selective Agonists Market Share by Application (2015-2020)

Table 45. Europe Key Players Selective Agonists Revenue (2019-2020) (Million US\$)

Table 46. Europe Key Players Selective Agonists Market Share (2019-2020)

Table 47. Europe Selective Agonists Market Size by Type (2015-2020) (Million US\$)

Table 48. Europe Selective Agonists Market Share by Type (2015-2020)

Table 49. Europe Selective Agonists Market Size by Application (2015-2020) (Million US\$)

Table 50. Europe Selective Agonists Market Share by Application (2015-2020)

Table 51. China Key Players Selective Agonists Revenue (2019-2020) (Million US\$)

Table 52. China Key Players Selective Agonists Market Share (2019-2020)

Table 53. China Selective Agonists Market Size by Type (2015-2020) (Million US\$)

Table 54. China Selective Agonists Market Share by Type (2015-2020)

Table 55. China Selective Agonists Market Size by Application (2015-2020) (Million US\$)

Table 56. China Selective Agonists Market Share by Application (2015-2020)

Table 57. Japan Key Players Selective Agonists Revenue (2019-2020) (Million US\$)

Table 58. Japan Key Players Selective Agonists Market Share (2019-2020)

Table 59. Japan Selective Agonists Market Size by Type (2015-2020) (Million US\$)

- Table 60. Japan Selective Agonists Market Share by Type (2015-2020)
- Table 61. Japan Selective Agonists Market Size by Application (2015-2020) (Million US\$)
- Table 62. Japan Selective Agonists Market Share by Application (2015-2020)
- Table 63. Southeast Asia Key Players Selective Agonists Revenue (2019-2020) (Million US\$)
- Table 64. Southeast Asia Key Players Selective Agonists Market Share (2019-2020)
- Table 65. Southeast Asia Selective Agonists Market Size by Type (2015-2020) (Million US\$)
- Table 66. Southeast Asia Selective Agonists Market Share by Type (2015-2020)
- Table 67. Southeast Asia Selective Agonists Market Size by Application (2015-2020) (Million US\$)
- Table 68. Southeast Asia Selective Agonists Market Share by Application (2015-2020)
- Table 69. India Key Players Selective Agonists Revenue (2019-2020) (Million US\$)
- Table 70. India Key Players Selective Agonists Market Share (2019-2020)
- Table 71. India Selective Agonists Market Size by Type (2015-2020) (Million US\$)
- Table 72. India Selective Agonists Market Share by Type (2015-2020)
- Table 73. India Selective Agonists Market Size by Application (2015-2020) (Million US\$)
- Table 74. India Selective Agonists Market Share by Application (2015-2020)
- Table 75. Central & South America Key Players Selective Agonists Revenue (2019-2020) (Million US\$)
- Table 76. Central & South America Key Players Selective Agonists Market Share (2019-2020)
- Table 77. Central & South America Selective Agonists Market Size by Type (2015-2020) (Million US\$)
- Table 78. Central & South America Selective Agonists Market Share by Type (2015-2020)
- Table 79. Central & South America Selective Agonists Market Size by Application (2015-2020) (Million US\$)
- Table 80. Central & South America Selective Agonists Market Share by Application (2015-2020)
- Table 81. Merck Company Details
- Table 82. Merck Business Overview
- Table 83. Merck Product
- Table 84. Merck Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 85. Merck Recent Development
- Table 86. Bausch Health Companies Company Details
- Table 87. Bausch Health Companies Business Overview
- Table 88. Bausch Health Companies Product

Table 89. Bausch Health Companies Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 90. Bausch Health Companies Recent Development

Table 91. Pfizer Company Details

Table 92. Pfizer Business Overview

Table 93. Pfizer Product

Table 94. Pfizer Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 95. Pfizer Recent Development

Table 96. Sterling Winthrop Company Details

Table 97. Sterling Winthrop Business Overview

Table 98. Sterling Winthrop Product

Table 99. Sterling Winthrop Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 100. Sterling Winthrop Recent Development

Table 101. Sanofi Company Details

Table 102. Sanofi Business Overview

Table 103. Sanofi Product

Table 104. Sanofi Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 105. Sanofi Recent Development

Table 106. Paragon BioTeck Company Details

Table 107. Paragon BioTeck Business Overview

Table 108. Paragon BioTeck Product

Table 109. Paragon BioTeck Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 110. Paragon BioTeck Recent Development

Table 111. West-Ward Pharmaceuticals Company Details

Table 112. West-Ward Pharmaceuticals Business Overview

Table 113. West-Ward Pharmaceuticals Product

Table 114. West-Ward Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 115. West-Ward Pharmaceuticals Recent Development

Table 116. Biosyent Pharma Business Overview

Table 117. Biosyent Pharma Product

Table 118. Biosyent Pharma Company Details

Table 119. Biosyent Pharma Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 120. Biosyent Pharma Recent Development

Table 121. Novartis Company Details

Table 122. Novartis Business Overview

- Table 123. Novartis Product
- Table 124. Novartis Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 125. Novartis Recent Development
- Table 126. Omega Laboratories Company Details
- Table 127. Omega Laboratories Business Overview
- Table 128. Omega Laboratories Product
- Table 129. Omega Laboratories Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 130. Omega Laboratories Recent Development
- Table 131. Medical Purchasing Solutions Company Details
- Table 132. Medical Purchasing Solutions Business Overview
- Table 133. Medical Purchasing Solutions Product
- Table 134. Medical Purchasing Solutions Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 135. Medical Purchasing Solutions Recent Development
- Table 136. Avadel Legacy Pharmaceuticals Company Details
- Table 137. Avadel Legacy Pharmaceuticals Business Overview
- Table 138. Avadel Legacy Pharmaceuticals Product
- Table 139. Avadel Legacy Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 140. Avadel Legacy Pharmaceuticals Recent Development
- Table 141. Amneal Biosciences Company Details
- Table 142. Amneal Biosciences Business Overview
- Table 143. Amneal Biosciences Product
- Table 144. Amneal Biosciences Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 145. Amneal Biosciences Recent Development
- Table 146. Cipla USA Company Details
- Table 147. Cipla USA Business Overview
- Table 148. Cipla USA Product
- Table 149. Cipla USA Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 150. Cipla USA Recent Development
- Table 151. Par Pharmaceutical Company Details
- Table 152. Par Pharmaceutical Business Overview
- Table 153. Par Pharmaceutical Product
- Table 154. Par Pharmaceutical Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 155. Par Pharmaceutical Recent Development

- Table 156. Glaxosmithkline Company Details
- Table 157. Glaxosmithkline Business Overview
- Table 158. Glaxosmithkline Product
- Table 159. Glaxosmithkline Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 160. Glaxosmithkline Recent Development
- Table 161. Teva Company Details
- Table 162. Teva Business Overview
- Table 163. Teva Product
- Table 164. Teva Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 165. Teva Recent Development
- Table 166. Bayer Company Details
- Table 167. Bayer Business Overview
- Table 168. Bayer Product
- Table 169. Bayer Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 170. Bayer Recent Development
- Table 171. Impax Generics Company Details
- Table 172. Impax Generics Business Overview
- Table 173. Impax Generics Product
- Table 174. Impax Generics Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 175. Impax Generics Recent Development
- Table 176. Mylan Pharmaceuticals Company Details
- Table 177. Mylan Pharmaceuticals Business Overview
- Table 178. Mylan Pharmaceuticals Product
- Table 179. Mylan Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 180. Mylan Pharmaceuticals Recent Development
- Table 181. Physicians Total Care Company Details
- Table 182. Physicians Total Care Business Overview
- Table 183. Physicians Total Care Product
- Table 184. Physicians Total Care Revenue in Selective Agonists Business (2015-2020) (Million US\$)
- Table 185. Physicians Total Care Recent Development
- Table 186. Cadila Pharmaceuticals Company Details
- Table 187. Cadila Pharmaceuticals Business Overview
- Table 188. Cadila Pharmaceuticals Product
- Table 189. Cadila Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 190. Cadila Pharmaceuticals Recent Development

Table 191. Alembic Pharmaceuticals Company Details

Table 192. Alembic Pharmaceuticals Business Overview

Table 193. Alembic Pharmaceuticals Product

Table 194. Alembic Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 195. Alembic Pharmaceuticals Recent Development

Table 196. Allergan Company Details

Table 197. Allergan Business Overview

Table 198. Allergan Product

Table 199. Allergan Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 200. Allergan Recent Development

Table 201. Mylan Company Details

Table 202. Mylan Business Overview

Table 203. Mylan Product

Table 204. Mylan Revenue in Selective Agonists Business (2015-2020) (Million US\$)

Table 205. Mylan Recent Development

Table 206. Research Programs/Design for This Report

Table 207. Key Data Information from Secondary Sources

Table 208. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Selective Agonists Market Share by Type: 2020 VS 2026
- Figure 2. ?1 Selective Agonists Features
- Figure 3. ?2 Selective Agonists Features
- Figure 4. ?1 Selective Agonists Features
- Figure 5. ?2 Selective Agonists Features
- Figure 6. Global Selective Agonists Market Share by Application: 2020 VS 2026
- Figure 7. Paroxysmal Supraventricular Tachycardia Case Studies
- Figure 8. Eye Drops Case Studies
- Figure 9. Anaphylaxis Case Studies
- Figure 10. Cardiac Arrest Case Studies
- Figure 11. Anaphylaxis Case Studies
- Figure 12. Cardiac Arrest Case Studies
- Figure 13. Chronic Heart Failure Case Studies
- Figure 14. Myocardial Infarction Case Studies
- Figure 15. Postoperative Hypotension Case Studies
- Figure 16. Selective Agonists Report Years Considered
- Figure 17. Global Selective Agonists Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 18. Global Selective Agonists Market Share by Regions: 2020 VS 2026
- Figure 19. Global Selective Agonists Market Share by Regions (2021-2026)
- Figure 20. Porter's Five Forces Analysis
- Figure 21. Global Selective Agonists Market Share by Players in 2019
- Figure 22. Global Top Selective Agonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Agonists as of 2019)
- Figure 23. The Top 10 and 5 Players Market Share by Selective Agonists Revenue in 2019
- Figure 24. North America Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. Europe Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 26. China Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 27. Japan Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 28. Southeast Asia Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 29. India Selective Agonists Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 30. Central & South America Selective Agonists Market Size YoY Growth

(2015-2020) (Million US\$)

Figure 31. Merck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Merck Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 33. Bausch Health Companies Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Bausch Health Companies Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 35. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Pfizer Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 37. Sterling Winthrop Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Sterling Winthrop Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 39. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Sanofi Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 41. Paragon BioTeck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Paragon BioTeck Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 43. West-Ward Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. West-Ward Pharmaceuticals Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 45. Biosyent Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Biosyent Pharma Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 47. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Novartis Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 49. Omega Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. Omega Laboratories Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 51. Medical Purchasing Solutions Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Medical Purchasing Solutions Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 53. Avadel Legacy Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. Avadel Legacy Pharmaceuticals Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 55. Amneal Biosciences Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Amneal Biosciences Revenue Growth Rate in Selective Agonists Business

(2015-2020)

Figure 57. Cipla USA Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Cipla USA Revenue Growth Rate in Selective Agonists Business

(2015-2020)

Figure 59. Par Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 60. Par Pharmaceutical Revenue Growth Rate in Selective Agonists Business

(2015-2020)

Figure 61. Glaxosmithkline Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 62. Glaxosmithkline Revenue Growth Rate in Selective Agonists Business

(2015-2020)

Figure 63. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 64. Teva Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 65. Bayer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 66. Bayer Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 67. Impax Generics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 68. Impax Generics Revenue Growth Rate in Selective Agonists Business

(2015-2020)

Figure 69. Mylan Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 70. Mylan Pharmaceuticals Revenue Growth Rate in Selective Agonists Business (2015-2020)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Selective Agonists Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/CD7C33B84445EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD7C33B84445EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

